Results
|
1.
|
|
|
2.
|
Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. [Review] MedStar authors:
Year: 2017
Citation: - Diabetologia. 60(9):1601-1611, 2017 Sep.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Crandall JP, Darwin C, Diabetes Prevention Program Research Group, Edelstein SL, Heckman-Stoddard BM, Jeffries SL, Kahn SE, Knowler WC, Molitch ME, Nathan DM, Perreault L, Pi-Sunyer X, Temprosa M
|
|
3.
|
Evaluating the potential benefits of metformin in patients with cardiovascular disease and heart failure. MedStar authors:
- Amin, Shril M
- Chilipko, Allison A
- Macharia, David
- Norwood, Daryn K
- Still, Kimberly L
Year: 2013
Citation: - Consultant Pharmacist. 28(9):579-83, 2013 Sep.
Institution: - MedStar Union Memorial Hospital
Medline publication type:
All authors: - Amin SM, Chilipko AA, Macharia D, Norwood DK, Still KL
|
|
4.
|
Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin. MedStar authors:
- Chen, Fang
- Lipinski, Michael J
- Pendyala, Lakshmana K
- Torguson, Rebecca
- Waksman, Ron
Citation: - Atherosclerosis. 235(2):295-8, 2014 Aug.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
- Journal Article
- Observational Study
All authors: - Chen F, Lipinski MJ, Pendyala LK, Torguson R, Waksman R
|
|
5.
|
|
|
6.
|
Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. MedStar authors:
Year: 2016
Citation: - Journal of Clinical Endocrinology & Metabolism. 101(4):1754-61, 2016 Apr
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Aroda VR, Bray GA, Crandall JP, Diabetes Prevention Program Research Group, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, Schade DS, Temprosa MG, White NH
|
|
7.
|
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. MedStar authors:
Year: 2017
Citation: - The Lancet Diabetes & Endocrinology. 5(5):355-366, 2017 May
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Axelsen M, Bain SC, Cariou B, DeVries JH, Piletic M, Rose L, Rowe E
|
|
8.
|
Genetic risk of progression to type 2 diabetes and response to intensive lifestyle or metformin in prediabetic women with and without a history of gestational diabetes mellitus. MedStar authors:
Year: 2014
Citation: - Diabetes Care. 37(4):909-11, 2014 Apr.
Institution: - MedStar Washington Hospital Center
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
All authors: - Christophi CA, Dabelea D, Dagogo-Jack S, Diabetes Prevention Program Research Group, Florez JC, Franks PW, Jablonski KA, Kim C, Knowler WC, Ratner R, Sullivan SD
|
|
9.
|
Metformin Attenuates 131I-Induced Decrease in Peripheral Blood Cells in Patients with Differentiated Thyroid Cancer. MedStar authors:
- Bikas, Athanasios
- Burman, Kenneth D
- Desale, Sameer
- Mete, Mihriye
- Van Nostrand, Douglas
- Wartofsky, Leonard
Year: 2016
Citation: - Thyroid. 26(2):280-6, 2016 Feb
Institution:
- MedStar Health Research Institute
- MedStar Heart & Vascular Institute
- MedStar Washington Hospital Center
Department:
- Medicine/Endocrinology
- Medicine/Nuclear Medicine
Medline publication type:
All authors: - Bikas A, Burman KD, Desale S, Jensen K, Mete M, Patel A, Van Nostrand D, Vasko V, Wartofsky L
|
|
10.
|
|
|
11.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(9):1579-86, 2016 Sep
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Diamant M, Fonseca V, LixiLan PoC Study Group, Perfetti R, Rosenstock J, Silvestre L, Souhami E, Zhou T
|
|
12.
|
Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. MedStar authors:
- Burman, Kenneth D
- Klubo-Gwiezdzinska, Joanna
- Mete, Mihriye
- Wartofsky, Leonard
Citation: - Journal of Clinical Endocrinology & Metabolism. 98(8):3269-79, 2013 Aug.
Institution:
- MedStar Health Research Institute
- MedStar Washington Hospital Center
Medline publication type:
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Bauer A, Burman KD, Costello J Jr, Jensen K, Klubo-Gwiezdzinska J, Mete M, Patel A, Vasko V, Wartofsky L
|
|
13.
|
|
|
14.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(11):1972-1980, 2016 Nov
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bellido D, Bergenstal RM, Gonzalez-Galvez G, Guo H, LixiLan-L Trial Investigators, Niemoeller E, Rosenstock J, Souhami E, Takami A, Unger J, Wysham C
|
|
15.
|
Clinical variability in approaches to polycystic ovary syndrome. MedStar authors:
Citation: - Journal of Pediatric & Adolescent Gynecology. 25(4):259-61, 2012 Aug.
Institution: - MedStar Washington Hospital Center
Department: - Obstetrics and Gynecology/Pediatric and Adolescent
Medline publication type:
All authors: - Appelbaum H, Bonny AE, Connor EL, Cromer B, DiVasta A, Gomez-Lobo V, Harel Z, Huppert J, NASPAG Research Committee, Sucato G
|
|
16.
|
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). MedStar authors:
Year: 2014
Citation: - Journal of Diabetes & its Complications. 28(3):386-92, 2014 May-Jun.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Boka G, Hanefeld M, Min KW, Miossec P, Muehlen-Bartmer I, Ratner RE, Rosenstock J, Shamanna P, Zhou T
|
|
17.
|
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). MedStar authors:
Year: 2017
Citation: - Diabetic Medicine. 34(12):1747-1755, 2017 Dec.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Barrett-Connor E, Dabelea D, Dagogo-Jack S, Hamman RF, Kahn SE, Knowler WC, Mather KJ, Pan Q, Perreault L, The Diabetes Prevention Program Research Group
|
|
18.
|
Gestational diabetes: implications for cardiovascular health. [Review] MedStar authors:
- Ratner, Robert E
- Sullivan, Shannon D
- Umans, Jason G
Year: 2012
Citation: - Current Diabetes Reports. 12(1):43-52, 2012 Feb.
Institution:
- MedStar Health Research Institute
- MedStar Washington Hospital Center
Medline publication type:
All authors: - Ratner R, Sullivan SD, Umans JG
|